The Connected Clinician: Top Stories of the Week for September 8

While you may have spent the first week of September looking back at your summer vacation photo albums, healthcare experts were also looking back — at studies recent and long-passed, at national statistics and at former guidelines. MD Mag's top headlines of the week featured a lot of review, and now is your chance to catch up on what you may have missed yourself.

From reconsidering pediatric wheezing treatment, to avoidable emergency department room visits and a review on movement disorder treatments, here's all the headlines from this week's Connected Clinician:

Men With Chronic Hepatitis C Infection See Faster Progression of Disease​

Researchers noted that some previous studies have found that sex hormones play a role in faster progression.

Lampalizumab Fails AMD Trial Goals, Delays Study

The investigational drug for geographic atrophy in AMD patients would be treating a majorly unmet need — if it succeeds.

C. difficile Fatalities Fall, But Cost and Length of Stay Increase

Despite declining fatalities, infection rates are climbing, especially among those on Medicare.

Increased Number of People in the US Living with HIV Are in Remission

While the national split is a significant jump from previously reported rates, the degrees of the success vary in different parts of the country.

Erenumab, Inhibitors Could Fill Unmet Gap in Migraine Care

Subcutaneous monoclonal antibodies could change the stagnant scope of migraine treatment.

Severe Asthma Remains Burden After Decade of Treatment

A 10-year follow-up of patients with severe asthma finds persistent illness remains difficult to treat.

Hepatitis B Vaccine Recommended for Infants Within 24 Hours of Birth

The vaccine is 75% to 95% effective in preventing perinatal hepatitis B transmission when given within 24 hours of birth, according to the AAP policy statement.​​​​​​

Secnidazole Meets Primary Endpoints in Phase 3 Trials for Bacterial Vaginosis

If approved, the drug will be the first and only single-dose oral therapy available or the condition.

Mavenclad Wins EU Approval After Reversal; FDA Application Coming Soon

Six years after it was initially rejected by regulators, a new relapsing remitting multiple sclerosis drug has been approved for sale in Europe.

New Research Highlights Role of Key Protein in HCV

Scientists now have a clearer understanding of how the protein NS5A gets around the body’s cellular defenses.